Posted by Michael Wonder on 22 Nov 2021
CRISPR Therapeutics announces FDA regenerative medicine advanced therapy designation granted to CTX110 for the treatment of relapsed or refractory CD19+ B-cell malignancies
22 November 2021 - CRISPR Therapeutics today announced that the U.S. FDA granted regenerative medicine advanced therapy designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.
CTX110, a wholly owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19, or CD19.
